

Supplementary

Table S1 The original data of the study

ID	Sex	Age at diagnosis	Age at continuing alectinib	Smoking history	Histology	Combination therapy	TNM stage at diagnosis	Brain metastases at diagnosis	Bone metastases at diagnosis	New brain metastases at PD	New bone metastasis at PD	Prior exposure to chemotherapy before alectinib	Prior exposure to ALK-TKI before alectinib	ECOG Performance Status in prior alectinib	ECOG Performance Status in continuing alectinib	Best response to prior alectinib	Best response to continuing alectinib	Line of prior Alectinib	PFS of prior alectinib	PFS of continuation of alectinib	Survival months	Progression type of prior alectinib	Progression of continuing alectinib	Vital status	Research center
1	Female	17	18	Unkown	adenocarcinoma	None	Stage IV	None	None	Yes	None	None	None	1	1	PR	SD	1	18	8	26	oligoprogression	None	Alive	Nanfang Hospital, Southern Medical University
15	Female	48	48	None	adenocarcinoma	Radiation	Stage IV	None	Yes	None	None	None	None	1	1	SD	SD	1	5	21	26	oligoprogression	None	Alive	Tang Du Hospital
10	Male	37	39	None	adenocarcinoma	Radiation	Stage IV	None	Yes	Yes	None	None	None	1	1	PR	PR	1	20	15	35	CNS progression	None	Alive	The First Affiliated Hospital of University of Science and Technology of China
4	Female	36	36	None	adenocarcinoma	Radiofrequency ablation	Stage IV	None	Yes	None	None	None	None	4	3	PR	PD	1	6	5	33	oligoprogression	Yes	Alive	General Hospital for EmergenciesThe First Affiliated Hospital of Xi'an Jiaotong University
5	Male	56	57	Unkown	adenocarcinoma	Radiation	Stage IV	None	None	Yes	None	None	crizotinib	2	2	PR	SD	2	9	13	61	CNS progression	Yes	Alive	The First Affiliated Hospital of Xi'an Jiaotong University
13	Female	28	29	None	adenocarcinoma	Radiation	Stage IV	None	Yes	Yes	None	None	None	1	1	PR	PR	1	18	12	44	CNS progression	Yes	Alive	Fudan University Tumor Hospital
3	Male	39	40	Unkown	adenocarcinoma	Radiation	Stage IV	Yes	None	None	None	None	crizotinib	2	2	PR	PD	1	12	8	54	CNS progression	Yes	Alive	The First Affiliated Hospital of Xi'an Jiaotong University
6	Female	57	58	None	adenocarcinoma	Radiation	Stage IV	Yes	None	Yes	None	None	None	1	1	PR	PR	1	18	7	25	CNS progression	Yes	Death	Fudan University Tumor Hospital
9	Female	48	48	None	adenocarcinoma	Chemotherapy	Stage IV	Yes	Yes	None	None	1 cycle of chemotherapy during post-diagnostic genetic test	crizotinib	2	2	SD	SD	2	7	2	60	CNS progression	Yes	Alive	The First Affiliated Hospital of Xi'an Jiaotong University
8	Female	41	41	None	adenocarcinoma	Radiation	Stage IV	None	None	None	None	None	None	2	2	PR	SD	1	8	4	17	oligoprogression	Yes	Alive	The First Affiliated Hospital of Xi'an Jiaotong University
7	Female	43	44	None	adenocarcinoma	Radiation	Stage IV	None	None	Yes	None	None	None	2	2	PR	PR	1	11	4	27	CNS progression	Yes	Alive	The First Affiliated Hospital of Xi'an Jiaotong University
12	Female	52	54	None	adenocarcinoma	None	Stage IV	None	None	None	None	None	None	1	1	PR	SD	1	31	13	44	oligoprogression	None	Alive	Shaanxi Provincial Tumor Hospital
2	Female	28	29	None	adenocarcinoma	Radiation	Stage IV	None	Yes	None	Yes	1 cycle of chemotherapy during post-diagnostic genetic test	None	2	2	PR	PR	1	12	3	32	oligoprogression	Yes	Alive	Shaanxi Province People's Hospital
11	Male	49	51	Yes	adenocarcinoma	Radiation	Stage IV	None	Yes	None	None	None	None	1	1	PR	PR	1	27	2	32	oligoprogression	Yes	Death	Nanfang Hospital, Southern Medical University
14	Male	56	59	None	adenocarcinoma	Bevacizumab	Stage IV	Yes	Yes	None	None	None	None	1	1	PR	PR	1	19	9	52	CNS progression	Yes	Alive	Shantou City Central Hospital

TNM, Tumor-Node-Metastasis staging system; PD, progression disease; ALK-TKI, anaplastic lymphoma kinase tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; PR, partial response; SD, stable disease; PD, progressive disease.